Miscellaneous ocular agents:
Indications for: SUSVIMO
In adults with neovascular (wet) age-related macular degeneration (AMD) who have previously responded to at least 2 intravitreal injections of a VEGF inhibitor.
See full labeling. Give by intravitreal implant. 2mg (0.02mL of 100mg/mL) continuously delivered via implant. Refill every 24 weeks (approx. 6 months). Supplemental treatment: 0.5mg (0.05mL of 10mg/mL) intravitreal inj into the affected eye while implant is in place, as clinically needed.
Ocular or periocular infections. Active intraocular inflammation.
Do not administer as bolus intravitreal inj. Do not substitute with other ranibizumab products. Monitor routinely following insertion. Endophthalmitis: treat promptly if occurs; delay dose (refill-exchange) until resolved. Rhegmatogenous retinal detachment: treat promptly; delay dose in presence of retinal detachment or retinal breaks. Evaluate retinal periphery prior to implant insertion. Risk of implant dislocation, vitreous hemorrhage, conjunctival blebs, conjunctival erosion or retraction. Decreased visual acuity for 2 months post-op. Improper filling of the implant due to air bubbles; see full labeling. Deflection of the implant due to eye procedures (eg, B-scan ultrasound, scleral depression, gonioscopy). Advise females of reproductive potential to use effective contraception during and for at least 12 months after the last dose. Pregnancy. Nursing mothers.
Vascular endothelial growth factor (VEGF) inhibitor.
Increased risk of vitreous hemorrhage with antithrombotic medication (eg, oral anticoagulants, aspirin, NSAIDs); temporarily interrupt these prior to implant insertion.
Conjunctival hemorrhage/hyperemia/edema, iritis, eye pain, vitreous floaters, foreign body sensation in eyes, headache, hypotony of eye, vitreous detachment, corneal disorder/abrasion/edema.
Generic Drug Availability:
Kit (single-dose vial + initial fill needle)—1; Single-dose vial—1; Refill needle—1